Aktie A3CU3W HEALTHWELL ACQUISITION CORP. I
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Healthwell Acquisition Corp. I

Aktien

A3CU3W

US42227R1095

HWEL

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Healthwell Acquisition Corp. I(NasdaqCM:HWEL) dropped from NASDAQ Composite Index
HEALTHWELL ACQUISITION CORP. I ANNOUNCES CANCELLATION OF SPECIAL STOCKHOLDER MEETING AND ITS INTENTION TO LIQUIDATE
Healthwell Acquisition Plans to Liquidate
Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate
Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I
Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.
Starton Therapeutics, Inc. cancelled the acquisition of Healthwell Acquisition Corp. I from a group of shareholders in a reverse merger transaction.
Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions
Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions
Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma
Top Premarket Gainers
Healthwell Acquisition Corp. I Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
Healthwell Acquisition I : Shareholder Director Nominations - Form 8-K
HEALTHWELL ACQUISITION CORP. I : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference
Healthwell Acquisition Corp. I Reports Earnings Results for the First Quarter Ended March 31, 2023
HEALTHWELL ACQUISITION CORP. I : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CU3W Aktie
  4. Nachrichten Healthwell Acquisition Corp. I
  5. Andere Sprachen